ITC Launches Section 337 Investigation on Antibody Drugs
The International Trade Commission began a Section 337 investigation on allegations that ProfoundBio, Genmab and their subsidiaries are importing and selling antibody drugs that infringe patents held by AbbVie Inc., and ImmunoGen, Inc. (ITC Inv. No. 337-TA-1466), it said in a notice to be published Dec. 22.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
The complaint was filed in November and seeks a limited exclusion order and cease and desist orders against the respondents to bar from entry "certain antibody drug conjugates products and components thereof and products containing the same" that violate the complainants' patents (see 2511200013).
AbbVie said in the complaint that its product, ELAHERE, is "a first-in-class ADC approved to treat adult patients with certain ovarian, fallopian tube, and primary peritoneal cancers."